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Smooth muscle cells (SMCs) are heterogeneous with respect to their contractile, synthetic, and proliferative properties,
though the regulatory factors responsible for their phenotypic diversity remain largely unknown. To further our
understanding of smooth muscle gene regulation, we characterized the cis-regulatory elements of the murine cysteine-rich
protein 1 gene (CRP1/Csrp1). CRP1 is expressed in all muscle cell types during embryogenesis and predominates in vascular
and visceral SMCs in the adult. We identified a 5-kb enhancer within the CRP1 gene that is sufficient to drive expression
in arterial but not venous or visceral SMCs in transgenic mice. This enhancer also exhibits region-specific activity in the
outflow tract of the heart and the somites. Within the 5-kb CRP1 enhancer, we found a single CArG box that binds serum
response factor (SRF), and by mutational analysis, demonstrate that the activity of the enhancer is dependent on this CArG
element. Our findings provide further evidence for the existence of distinct regulatory programs within SMCs and suggest
a role for SRF in the activation of the CRP1 gene. © 2001 Elsevier Science
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In vertebrate organisms, smooth muscle cells (SMCs) are
a vital component of the respiratory, urogenital, circula-
tory, and digestive systems. As mature cells, they exhibit an
array of contractile, proliferative, and physiological charac-
teristics (Owens, 1995). This phenotypic diversity is
thought to arise as a result of their multiple origins, and is
necessitated by their requirement to perform a range of
specialized functions. Despite numerous studies of smooth
muscle biology, our understanding of the molecular mecha-
nisms that govern the formation and subsequent modula-
tion of SMCs is greatly limited.
1 To whom correspondence should be addressed. Fax: (801) 581-
2175. E-mail: brenda.lilly@hci.utah.edu.
Abbreviations: bp, base pairs; CRP, cysteine-rich protein; E,
embryonic day of gestation; kb, kilobases; LacZ, b-galactosidase;
RACE, rapid amplification of cDNA ends; (RT)PCR, (reverse tran-
scriptase) polymerase chain reaction; SMC(s), smooth muscle
cell(s); SRF, serum response factor.
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All rights reserved.To elucidate the regulatory pathways that control SMC
gene expression, several genes expressed in SMCs have been
characterized to identify the cis-acting elements and trans-
acting factors responsible for their expression. These in-
clude genes that encode smooth muscle a-actin, smooth
muscle myosin heavy chain, telokin, calponin, and the
calponin-like protein SM22a (reviewed in Solway et al.,
1998). An emerging theme arising from these studies is that
separate regulatory cassettes dictate gene expression in
distinct SMC populations. For example, a 445-bp region of
the SM22a gene is sufficient to drive expression in arterial
SMCs, but does not support expression in venous or visceral
SMCs (Kim et al., 1997; Li et al., 1996; Moessler et al.,
1996). The existence of separate regulatory elements for
subpopulations of SMCs indicates that the transcriptional
machinery that functions on these enhancers is accordingly
distinct. Several transcription factors and their respective
cis-elements have been implicated in the control of smooth
muscle-specific gene expression. These factors include SRF,
MEF2, GATA-6, Sp1, and YY1; however, none are exclu-
sively expressed in SMCs (reviewed in Solway et al., 1998).
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532 Lilly, Olson, and BeckerleThe absence of a smooth muscle-restricted regulator im-
plies that smooth muscle determinants must function in a
combinatorial fashion that is dependent on the collective
organization of cis sequences. One cis-element common to
all smooth muscle genes characterized to date is the CArG
box [CC(A/T)6GG], which binds serum response factor
(SRF) (Shore and Sharrocks, 1995). Numerous studies have
demonstrated the importance of SRF and the CArG element
for SMC gene expression, and in addition, for expression of
genes in cardiac and skeletal muscle cells (reviewed in
Reecy et al., 1998). SRF is thought to selectively activate
genes in distinct populations of muscle cells through inter-
actions with myogenic cofactors, which convey its cell-
specific function. Consistent with this notion, the cardiac
transcription factors GATA-4 and Nkx2.5 cooperate with
SRF and promote transcriptional activity (Belaguli et al.,
2000; Chen and Schwartz, 1996; Morin et al., 2001). Re-
cently, a potent transcriptional activator of the SAP (SAF-
A/B, Acinus, PIAS) domain family, named myocardin, has
been shown to form a ternary complex with SRF and
selectively activate muscle genes in a CArG box-dependent
manner (Wang et al., 2001). Myocardin is expressed in
cardiac and smooth muscle, and thus may cooperate with
FIG. 1. (A) Diagram of the genomic structure of the murine CRP1
The intron/exon organization of the CRP1 gene is shown with boxe
bp, (2) 112 bp, (3) 167 bp, (4) 130 bp, (5) 93 bp, and (6) 403 bp. Trans
and 1B. (B) RT-PCR amplification of unique transcripts encoded by
exon 1A and 1B are 157 bp and 132 bp, respectively. Larger bands v
of the nested PCR procedure. (C) Control RT-PCR reaction identicSRF to precisely activate genes in these myogenic lineages.
© 2001 Elsevier Science. AHence, the prevailing question is how separate regulatory
elements decipher the interactions of SRF and its cofactors
to direct expression in discrete muscle-cell populations.
In an effort to further our understanding of the mecha-
nisms that control smooth muscle gene expression, we
characterized the regulatory regions of the smooth muscle-
expressed cysteine-rich protein 1 gene (CRP1/Csrp1)2 (Hen-
derson et al., 1999; Louis et al., 1997). Members of the CRP
family, including CRP1, CRP2/smLIM (Jain et al., 1996;
Louis et al., 1997), and CRP3/MLP (Arber et al., 1994; Louis
et al., 1997), code for proteins with a pair of tandemly
arrayed LIM domains, each of which is linked to a glycine-
rich repeat. The CRPs are enriched in muscle cells where
they predominately associate with the actin-based cy-
toskeleton (Arber et al., 1994; Crawford et al., 1994; Louis
et al., 1997; Sadler et al., 1992). The function of CRP1 has
not been established, though targeted deletion of the CRP3/
MLP gene has demonstrated a role for this CRP family
member in contractile apparatus organization and myofibril
integrity within the heart (Arber et al., 1997; Ehler et al.,
2 Csrp1 is the official symbol of the cysteine-rich protein 1 gene.
The locus encompasses approximately 30 kb of genomic sequence.
ns (not to scale). Actual sizes of the exons are (1A) 129 bp, (1B) 417
ion start sites are indicated by right-angled arrows above exon 1A
1A and 1B to assess promoter usage. Amplified PCR products from
in certain lanes are products from the first amplification reaction
(B), except reverse transcriptase was omitted from the reactions.gene.
d exo
cript
exon
isibleHere we have used the conventional symbol to refer to the gene
encoding the cysteine-rich protein 1.
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533Expression of a CRP1 Enhancer in Smooth Muscle Cells2001). Given the extensive structural similarity among the
CRP family members, CRP1 may have an analogous func-
tion within SMCs.
In this study, we describe the characterization of an
enhancer element that controls expression of the CRP1
gene in SMCs. By analysis of transgenic mice harboring
fragments of the CRP1 gene fused to a LacZ reporter, we
identified a 5-kb enhancer within an intron of CRP1 (CRP1-
5.0) that confers expression within arterial SMCs. The
activity of the CRP-5.0 transgene is limited to a subgroup of
cells in which the endogenous CRP1 gene is expressed.
CRP1 transcripts are present in both visceral and vascular
SMCs; however, the 5-kb enhancer is insufficient for ex-
pression within visceral muscles and the venous system.
Within the enhancer, we identified a CArG box that is
capable of binding SRF and by mutational analysis we
demonstrated that this CArG element is essential for the
activity of the enhancer in vivo. Our results provide addi-
tional evidence for the existence of distinct regulatory
programs in vascular and visceral SMCs and suggest a role
for SRF in the activation of CRP1 gene expression.
MATERIALS AND METHODS
Mapping of the CRP1 Genomic Locus
The genomic organization of the CRP1 gene (Fig. 1) was deter-
mined by standard molecular techniques (Sambrook et al., 1989).
FIG. 2. CRP1 transgenes used to identify enhancer activity in vivo
shown below as rectangular boxes. Each fragment was cloned into
mouse embryos at day 16.5 of gestation. The B19, H12, and CRP1-5
sizes are (1A) 5.5 kb, (1B) 7 kb, (B19) 19 kb, (H12) 12kb, and (CRP1
FIG. 3. LacZ expression of the CRP1-5.0 enhancer in embryos
histological sections (C–E) of mouse embryos harboring the CRP1
in the dorsal aorta (da), aortic sac (as), first branchial arch (ba), bulb
intense LacZ expression is observed in the vasculature and the trun
portion of the heart reveals expression in the aortic sac wall (as), an
caudal section showing LacZ activity surrounding the aorta (a), and
tract into the aortic (at), and pulmonary trunks (pt). Expression is co
of the heart. Aortic arches (ar), branchial arch (ba), carotid artery (c
(ua), ventricle (v).
© 2001 Elsevier Science. ABacterial Artificial Chromosome (BAC) clones from a mouse ES-
129SvJ library (Genome Systems) were isolated by using the
full-length CRP1 cDNA as a probe. One of these BAC clones
containing the entire CRP1 gene was mapped relative to the cDNA
by restriction enzyme digests and Southern blot analysis. Organi-
zation of the BAC clone was confirmed with parallel Southern blots
by using mouse 129SvJ genomic DNA. Splice sites of the intron/
exon boundaries were identified by sequencing across junctions
with primers made to cDNA sequences. Sequencing was performed
at the University of Utah DNA Sequencing Facility. Primers were
synthesized at the University of Utah Oligonucleotide Synthesis
Facility.
Detection and Mapping of the 5* Exons by RT-PCR
and RACE
To assay for the presence of the unique 59 exons, RT-PCR was
performed by using a nested PCR strategy on RNA derived from
smooth muscle tissues. Primer sets consisted of unique 59 to 39
primers for exons 1A and 1B and common 39 to 59 primers within
downstream exons. Total RNA for the RT-PCRs was isolated from
adult mouse tissues and embryos by using TRIzol (Life Technolo-
gies). cDNA was generated by M-MLV reverse transcriptase (Life
Technologies) using 1 mg of RNA according to manufacturer’s
instructions. PCR samples contained 13 PCR buffer (Life Tech-
nologies), 2 mM MgCl2, 200 mM dNTPs, 15 mM of each primer, and
1 unit Taq DNA polymerase (Life Technologies). The transcription
start sites were identified by RACE using the Clontech Ampli-
finder kit with a nested PCR procedure. cDNA was synthesized
from RNA isolated from the intestine and aorta by using M-MLV
gram of the CRP1 locus with regions used to construct transgenes
Z reporter vector and tested transiently for enhancer expression in
nsgenes exhibited LacZ activity within the vasculature. Fragment
5 kb.
9.5 to E12.0. Whole-mount preparations (A, B), and transverse
acZ transgene. (A) Embryo at stage E9.5, LacZ activity is present
rdis (bc) of the heart, and the rostral-most somites (s). (B) By E11.5,
rteriousus (ta) of the heart (h). (C) E11.5, section through the rostral
red aorta (a). No expression lines the cardinal veins (cv). (D) E11.5,
bilateral premuscle masses (m). (E) E12.0, septation of the outflow
d to the forming outflow vessels and is not present in the chambers
ft atrium (la), right atrium (ra), spiral septum (ss), umbilical artery. Dia
a Lacat E
-5.0-L
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535Expression of a CRP1 Enhancer in Smooth Muscle CellsFIG. 4. Expression of the CRP1-5.0-LacZ transgene at E13.5 and E14.5, and in neonates. Detection of activity from the CRP1-5.0-LacZ
transgene in whole-mount preparations (A–C and G) and transverse histological sections (D–F). (A) Embryo at stage E13.5 shows restricted
expression to the arterial vascular system (B) Higher magnification of E13.5 embryo shows arteries infiltrating visceral tissues, pulmonary
arteries (pa), and abdominal arteries (aa). No expression is observed in the SMCs lining the visceral organs. (C) Transgene expression at E14.5
is evident in all arterial vessels present at this time, and in the skeletal muscle fibers (sk) along the body axis. Additional staining of the
perichondral mesenchyme (pm) is also present. The apparent signal seen in the heart is deceptive and in fact represents diffusion of stain
into the pericardial cavity from the outflow vessels (see F). (D) Arterial vessel from embryo at E14.5 reveals transgene activity in the SMCs
(smc) surrounding the vessel lumen. The inner layer of endothelial cells (en) do not express the transgene. (E) E14.5, section through the
lungs demonstrates expression in the pulmonary arteries (pa), while the SMCs lining the pulmonary veins (pv) and bronchial tubes (b) are
unstained. (F) E14.5, section through the heart shows no expression in the atrial and ventricular chambers. LacZ activity surrounds the
opening of the aortic valve (av), and is also present in the atrio-ventricular cushion (ac). (G) Dissected heart and lungs from 3-day-old
neonate. Expression is seen in the aorta (a), and branched pulmonary arteries (pa) of the lungs (L), as well as the left atria (la), and right atria
(ra). Weak punctate staining is observed in the ventricles. Aorta (a), cranial arteries (c), dorsal aorta (da), heart (h), kidney (k), left atria (la),
left ventricle (lv), outflow tract (ot), perichondral mesenchyme (pm), right atria (ra), right ventricle (rv), vena cava (vc).
© 2001 Elsevier Science. All rights reserved.
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536 Lilly, Olson, and Beckerlereverse transcriptase (Life Technologies). The first round of PCR
was performed by using the RACE 59 to 39 anchor primer (Clontech)
FIG. 5. Analysis of CRP1-5.0 enhancer fragments in cultured cel
the pGL3-Luciferase reporter vector. The 5.0-kb fragment was use
Enhancer activity was examined transiently in (A) PAC1 smooth m
and primary cultures of bovine aortic endothelial cells (BAEC). Th
serum (growth) or under differentiation conditions with 2% horse
parent pGL3-luciferase construct, set at 1. Data presented representhat was ligated to 59 ends of cDNAs, and a 39 to 59 primer to CRP1
© 2001 Elsevier Science. Asequences common to both transcripts in exon 2. The second round
of PCR used the same RACE anchor primer with exon-specific 39 to
hancer fragments were cloned upstream of the SV40 promoter in
generate the smaller constructs with the restriction sites shown.
e cells and 10T1/2 fibroblasts and (B) C2C12 skeletal muscle cells
C12 cells were tested in growth conditions with 10% fetal bovine
(diff). Luciferase activities are presented as fold-activity over the
averages of four independent assays. Error bars reflect 6 SEM.ls. En
d to
uscl
e C259 primers to amplify exon 1A or 1B. Nested PCR products from the
ll rights reserved.
537Expression of a CRP1 Enhancer in Smooth Muscle CellsFIG. 6. Nucleotide sequence of the 1.9-kb enhancer that confers activity in cultured smooth and skeletal muscle cells. Within the CRP1
gene the enhancer is located in an intron with the 59 end positioned approximately 1.3-kb downstream of exon 1B. Sequence is shown 59
to 39 with nucleotides numbered on the right. Putative cis-acting elements are underlined. A single CArG box is located at nucleotide
position 1471.
© 2001 Elsevier Science. All rights reserved.
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538 Lilly, Olson, and Beckerleindividual reactions were subcloned into pBluescript (Stratagene)
and four clones from each reaction were sequenced to determine
the 59 end of the cDNA sequence.
Production and Analysis of Transgenic Animals
To test for enhancer activity in transgenic mice, fragments of the
CRP1 locus (Fig. 2) were cloned into LacZ reporter vectors and
analyzed for activity either transiently or in established transgenic
lines. DNA constructs to test the upstream promoter regions (1A
and 1B) were cloned into a promoter-less LacZ reporter vector,
pBSSK-AUGbGal (Cheng et al., 1993), and were designed to utilize
each of the CRP1 promoters. Genomic fragments encompassing
the promoter regions (B19 and H12) and the 5-kb intronic enhancer
(CRP1-5.0) were subcloned into the hsp68LacZ expression vector,
which has been described previously (Logan et al., 1993). The CArG
mutation was introduced into the CRP1-5.0-LacZ construct by
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
Transgenic mice were generated by using standard protocols
(Hogan et al., 1994). For transient analysis, F0 injected embryos
were sacrificed at the indicated days of gestation and examined for
LacZ activity. DNA isolated from the yolk sacs of these embryos
was used to test for construct integration by Southern blot analysis.
FIG. 7. (A) Gel mobility shift assays with the CRP1-CArG elem
mobility shift assays with a radiolabeled CRP1-CArG element a
competitors in designated binding reactions to demonstrate speci
within these complexes were performed by addition of either the
extracts, the CRP1-CArG element binds to complexes that are r
enhancer by SRF-VP16. 10T1/2 cells were transfected with either
mutated CArG element. Sequences of the wild-type and mutant C
expression vectors containing no insert (CMV), SRF, or SRF-VP16
average of three independent experiments. Error bars represent 6Stable transgenic lines harboring the CRP1-5.0-LacZ construct
were generated by raising F0 pups and testing for construct integra-
© 2001 Elsevier Science. Ation by Southern blot analysis of tail DNA. The F0 founder animals
were mated to establish independent lines and mice from these
lines were then used to analyze enhancer activity in embryos at
various stages of development. To detect enhancer activity, em-
bryos were isolated by dissection in PBS (phosphate-buffered saline)
and fixed in 2% formaldehyde, 0.2% gluteraldehyde for 1–2 h
(Cheng et al., 1993). Embryos were then rinsed in PBS and placed in
staining solution overnight at room temperature. The staining
solution to detect LacZ activity consisted of 5 mM K4Fe(CN)6, 5
mM K3Fe(CN)6, 2 mM MgCl2, 0.02% NP-40, and 0.1% X-gal in PBS
buffer. After staining, embryos were postfixed with 4% formalde-
hyde overnight and dehydrated in a methanol series the following
day. For better visualization, embryos were cleared in a solution of
2 volumes of benzyl benzoate per 1 volume of benzyl alcohol for
1–3 h. For histological sectioning, embryos were cleared with
xylene and embedded in paraffin. Embryos were sectioned on a
microtome at a thickness of 4 mm and counterstained with hema-
toxylin eosin. Tissues were dissected from adult animals, fixed for
2 h, and stained as described above.
Constructs Used for Transfections
To analyze enhancer activity in culture, enhancer fragments
were cloned into the pGL3-Promoter-Luciferase reporter (Pro-
Nuclear extracts from 10T1/2 and PAC1 cells were used in gel
robe. Unlabeled doubled-stranded oligonucleotides were used as
of the shifted complexes. Supershift assays to identify proteins
or YY1 antisera to indicated reactions. In both 10T1/2 and PAC1
nized by the SRF antibody. (B) Transactivation of the CRP1-5.0
CRP1-5.0-Luc construct or CRP1-5.0mutCArG-Luc, containing a
elements are shown. Enhancer constructs were cotransfected with
ciferase activities are presented as fold-activity and represent theent.
s a p
ficity
SRF
ecog
the
ArG
. Lumega), containing the SV40 promoter fused to luciferase. Enhancer
ll rights reserved.
539Expression of a CRP1 Enhancer in Smooth Muscle CellsFIG. 8. Consequence of a CArG box mutation on CRP1-5.0 enhancer activity. (A, B) A CArG mutation was introduced into the
CRP1-5.0-LacZ transgene (CRP1-5.0mutCArG-LacZ), and its activity was assessed in F0 transgenic embryos at days E11.5 and E12.0.
Embryos harboring the CRP1-5.0mutCArG-LacZ transgene exhibit a dramatic reduction of LacZ expression. In comparison to the wild-type
pattern (A), expression is abolished in the vasculature and only weak activity remains in the outflow tract (B). Dorsal aorta (da), outflow
tract (ot), perichondral mesenchyme (pm), somites (s). (C) Analysis of the CArG mutation in cultured cells. CRP1-5.0 luciferase constructs
were transiently transfected into PAC1 and C2C12 cells and assayed for reporter activity. Activities of the wild-type (CRP1-5.0-Luc) and
mutant (CRP1-5.0mutCArG-Luc) enhancers were measured relative to the parent luciferase construct (pGL3-Luc), and are presented as
fold-activity, set at 1. Results are the average of three independent experiments. Error bars represent 6 SEM.
© 2001 Elsevier Science. All rights reserved.
540 Lilly, Olson, and Beckerlefragments were cloned upstream of the promoter within the
multicloning region by using restriction sites designated in Fig. 5,
with the exception of CRP1-1.4, which was cloned as a BamHI
insert. The same CRP1-5.0 fragment used for transgenic analysis
was cloned into the luciferase reporter with a 59 SmaI site located
within the intron and differed from the transgene in that it lacked
the 39 portion of exon 1B and 190 bases of intronic sequence.
Mutagenesis of the CArG element was performed with the
QuikChange Site-Directed Mutagenesis Kit (Stratagene) by using
the wild-type CRP1-5.0-Luciferase vector as template.
Transient Transfections and Reporter Assays
Cultured cells used for transfection experiments were grown in
D-MEM (Life Technologies) supplemented with 10% fetal calf
serum. 10T1/2 fibroblasts and C2C12 skeletal muscle cells were
obtained from the American Type Culture Collection (ATCC).
PAC1 smooth muscle cells derived from rat pulmonary arteries
(Rothman et al., 1992) were a gift from Joe Miano (University of
Rochester). Bovine aortic endothelial cells (BAEC) were purchased
from Clonetics Inc. Cells were transiently transfected at 60–70%
confluency by using Lipofectamine (Life Technologies) and har-
vested 48 h after the start of transfection. The amount of each
reporter construct used was 1.5 mg for 10T1/2 and C2C12 cells and
2 mg for PAC1 and BAEC cells. To normalize for transfection
efficiency, 0.5 mg of either the CMV-LacZ or hsp68-LacZ reporter
construct was cotransfected and luciferase activities were calcu-
lated based on equivalent amounts of LacZ activity. Cells were
harvested and LacZ activities were measured as described (Neville
and Hauschka, 1998). Luciferase assays were performed as de-
scribed (Ausubel, 1995) and quantified using a Dynex Luminom-
eter. Each experiment was repeated a minimum of three times and
LacZ and luciferase assays were measured in duplicate. For cotrans-
fection experiments with SRF, 1 mg of the designated expression
construct was transfected with the luciferase reporters as described
above. The expression constructs were MLV-SRF and MLV-SRF-
VP16 (Hill et al., 1994), obtained from A. Thorburn, and a control
plasmid, pCDNA1.1 (Novagen), containing the CMV promoter
without insert.
Gel Mobility Shift Assays
Gel mobility shift assays were performed essentially as de-
scribed (Gossett et al., 1989). Briefly, 50 ng of the CRP1-CArG
probe was labeled with [32P]dCTP by a fill-in reaction, purified on
a 10% polyacrylamide/0.53 TBE gel, and the amount of radio-
activity was quantified. Nuclear extracts were isolated and
prepared as described (Gossett et al., 1989). For each reaction, 10
mg of nuclear extract, 0.5 mg of poly(dI-dC), and approximately
0.01 pmoles of probe were incubated in 13 binding buffer (15
mM Hepes, pH 7.9, 40 mM KCl, 1 mM EDTA, 0.5 mM DTT, and
20% glycerol). For competition experiments, 100-fold molar
excess (1 pmole) of unlabeled double-stranded oligonucleotide
competitor was added 5 min prior to addition of the probe.
Reactions were incubated for a total of 20 min at room tempera-
ture. For antibody supershifts, 1 ml of the SRF (Santa Cruz, G-20)
or YY1 (Santa Cruz, H-10) antibody was added to the reaction 10
min prior to sample loading. Samples were electrophoresed on a
6% polyacrylamide/0.53 TBE gel at 120V for 2 h, dried, and
exposed to Hyper-film (Kodak) for 18 h. The oligonucleotides
used for probes and competition experiments were: (U) upper
strand, (L) lower strand (linker nucleotides are shown as lower-
© 2001 Elsevier Science. Acase): SRE (U): 59-gatcGATGTCCATATTAGGACATC, SRE (L):
59-gatcGATGTCCTAATATGGACATC, CRP1-CArG (U): 59-gatcc-
TTCCCATGTATGGTAAg, CRP1-CArG (L): 59-gatccTTACCAT-
ACATGGGAAg, mutCArG (U): 59- GGTAATTCGCATGTATAG-
TAAAGTG, mutCArG (L): 59-CACTTTACTATACATGCGAA-
TTACC.
RESULTS
Mapping of the Intron/Exon Organization of the
Murine CRP1 Gene
As a first step toward defining the regulatory elements of
the CRP1 gene, we mapped the intron/exon organization of
the murine CRP1 locus. The CRP1 gene spans approxi-
mately 30 kb of genomic sequence and is comprised of 7
exons (designated as 1A, 1B, and 2–6; Fig. 1A). Exons 2–6
contain the entire protein coding sequence, with the initi-
ating methionine beginning at nucleotide 2 in exon 2. The
first LIM domain (amino acids 10–61) resides in exons 2 and
3, and the second LIM domain (amino acids 119–170) spans
exons 4 through 6. The genomic organization of the mouse
CRP1 gene is very similar to the CRP2 gene (Yet et al.,
1998). The CRP1 and CRP2 proteins are 78% identical and
the conserved amino acids precisely align with one another.
A comparison of their genomic structures revealed that the
coding exons are spliced at identical positions within the
codons, and the introns that separate these exons are
similar in size. This strong genomic homology provides
additional evidence that the CRP genes are descendents of a
common ancestor and have arisen as two independent loci
through gene duplication.
In contrast to the structural similarity of the CRP genes
within their coding regions, these two genes have diverged
from one another at their 59 ends. CRP2 contains a single 59
untranslated exon, whereas CRP1 has two 59 untranslated
exons that correspond to regions of two distinct mRNAs.
The two upstream exons within CRP1 were initially iden-
tified from cDNA libraries and the transcription start sites
were mapped by rapid amplification of cDNA ends (RACE).
Isolated CRP1 transcripts contained 59-most sequences
from either exon 1A or 1B, but never both, indicating the
presence of two independent promoters. Sequence analysis
of the 1A promoter revealed a TATA-like element (TT-
TAAA) at 2100, Sp1 and E-box motifs, and a MEF2 element
(data not shown). The 1B promoter region lacked a recog-
nizable TATA-box, and had several consensus elements for
the Nkx2.5 homeodomain protein and the zinc-finger
GATA factors, in addition to a number of AP-1 sites (data
not shown).
The identification of two transcription initiation sites led
us to ask whether the two promoters were being selectively
utilized in smooth muscle tissues. To test this, we pre-
formed RT-PCR to detect the unique exons downstream of
each promoter (Figs. 1B and 1C). PCR products amplified
from exon 1A or exon 1B were both detected in RNA
samples isolated from whole embryos, and the aorta, intes-
ll rights reserved.
541Expression of a CRP1 Enhancer in Smooth Muscle Cellstine, kidney, lung, and uterus of adult mice, indicating that
transcription is occurring from both promoters in these
tissues. The selective utilization of these promoters may
occur at a more refined level, which we were unable to
resolve using RNA derived from whole tissues. Possibly
these promoters are preferentially used in subpopulations of
SMCs that manifest subtle, yet phenotypically distinct
characteristics within these tissues.
Identification of a CRP1 Enhancer in Transgenic
Mice
To define the enhancer elements responsible for the
expression of CRP1 in smooth muscle cells, we generated
transgenic mice harboring fragments of the CRP1 gene
fused to a LacZ reporter. The CRP1 fragments tested in
transgenic animals are depicted in Fig. 2. As an initial
screen for enhancer activity, we examined DNA fragments
by transient analysis, staining for LacZ expression in F0
embryos at embryonic day 16.5 (E16.5). At this stage, CRP1
transcripts are abundant in both vascular and visceral
smooth muscle tissues (Henderson et al., 1999; Jain et al.,
1998). The first transgenes tested were derived from the
promoter regions, containing 5.5 kb upstream of 1A and 7
kb upstream of 1B. Two F0 embryos containing the 1A
transgene, and two with the 1B transgene were determined
to have integrated constructs by Southern blot analysis, yet
showed no LacZ expression. For the analysis of larger
fragments that encompassed the 1A and 1B promoters, we
used a LacZ reporter containing the hsp68 basal promoter,
which alone is transcriptionally silent in mouse embryos
(Logan et al., 1993). Three F0 embryos harboring the B19
(19-kb) transgene, and nine F0 embryos containing the H12
(12-kb) transgene showed comparable patterns of LacZ
staining. Both LacZ constructs were expressed in the vas-
culature and exhibited no activity in visceral SMCs of E16.5
embryos (data not shown). From the preliminary results of
the four transgenes examined, we reasoned that enhancer
activity potentially resided in the 39 region of the B19 and
H12 fragments, positioned within the intron downstream of
exon 1B (Fig. 2). We therefore created a hsp68-LacZ con-
struct containing the 5-kb fragment (CRP1-5.0) from this
intronic region. Indeed, the CRP1-5.0-LacZ transgene was
sufficient for expression in the vasculature at E16.5, and
thus we chose to focus on this 5-kb enhancer element in an
attempt to further characterize its activity.
Expression of the CRP1–5.0-LacZ Transgene in
Myogenic Lineages
To characterize the expression profile of the CRP1-5.0
enhancer, we generated two independent transgenic lines
possessing stable integrated copies of the CRP1-5.0-LacZ
transgene, and examined LacZ activity throughout devel-
opment and in adult mice. To further verify the expression
pattern of the enhancer in these founder lines, we also
assessed LacZ activity in F0 embryos at E11.5 and E13.5.
© 2001 Elsevier Science. AThe temporospatial expression of the CRP1-5.0-LacZ trans-
gene was highly reproducible within six independent F0
animals and the two stable lines, with only slight variations
seen in the intensity of the LacZ signal.
Expression of the CRP1-5.0-LacZ transgene was first
detected in the developing vasculature between E8.5 and
E9.0 (data not shown). At E9.5, LacZ activity was clearly
evident in the dorsal aorta, the first branchial arch artery,
the aortic sac, and the bulbus cordis of the heart (Fig. 3A).
From the earliest stage of expression, the CRP1-5.0-LacZ
transgene exhibited region-specific activity within the bul-
bus cordis, with pronounced staining in the anterior region
that abruptly declined posteriorly. Embryos at E9.5 also
expressed the transgene in the rostral-most somites (Fig.
3A). Somite expression was coincident with the onset of
somite maturation, beginning at E9.0, and was restricted to
the myotomal compartment harboring the skeletal muscle
progenitor cells (data not shown).
By day E10.0, the LacZ pattern exhibited a uniform
appearance that closely resembled the expression seen in
older embryos at E11.5 (Fig. 3B). Expression persisted in the
dorsal aorta and aortic sac, and was readily apparent in the
umbilical, carotid, and aortic arch arteries (Figs. 3B and 3C).
Transverse sections of E11.5 embryos showed that the LacZ
activity was confined to layers of cells immediately sur-
rounding the lumen of arterial vessels, corresponding to
SMCs (Figs. 3C and 3D). Conversely, no staining was
evident in the cardinal or umbilical veins at this stage.
Histological sections also revealed that, following disper-
sion of the somites, the transgene was expressed in the
preskeletal muscle masses positioned bilaterally along the
body axis (Fig. 3D). Within the heart, partitioning of the
bulbus cordis by the formation of the bulbo-ventricular
groove showed that the CRP1-5.0-LacZ transgene was spe-
cific to the truncus arteriousus, the presumptive outflow
tract (Fig. 3B). Diffuse staining was observed in the primi-
tive ventricles, positioned posteriorly to the bulbo-
ventricular junction, while no expression was observed in
the atria (Fig. 3C). At E10.0, the outflow tract begins to be
divided into the aortic and pulmonary trunks with the
inception of the spiral septum. In embryos at day 12, the
spiral septum is clearly visible and transgene expression
was apparent in the walls of both the pulmonary and aortic
channels (Fig. 3E).
Expression of the CRP1-5.0-LacZ transgene in these early
stages was confined to smooth, cardiac, and skeletal muscle
precursor cells. In the vasculature, activation of the CRP1-
5.0 enhancer coincides with the onset of the endogenous
gene’s expression in SMCs, and parallels that of the smooth
muscle a-actin gene, which is the earliest known marker of
definitive SMCs (McHugh, 1995). The transgene recapitu-
lated the expression of CRP1 transcripts in the arterial
SMCs and the somites, though differed from the endoge-
nous gene within the heart. In situ analysis of the CRP1
gene demonstrated that transcripts are present in all cham-
bers of the heart during embryogenesis (Henderson et al.,
1999). However, the activity of the CRP1-5.0-LacZ trans-
ll rights reserved.
542 Lilly, Olson, and Beckerlegene was limited to cells of the outflow tract, indicating
that separate regulatory cassettes govern expression of
CRP1 in the embryonic heart.
Vascular Expression of the CRP1–5.0-LacZ
Transgene Is Restricted to Arterial SMCs
With the progression of embryogenesis, the complexity of
the CRP1-5.0 enhancer’s expression in the vasculature
gradually increased. In embryos at E13.5 and E14.5, the
transgene was expressed in all arteries seen infiltrating the
organs and tissues of the body (Figs. 4A–4C). These vessels
included the cranial, abdominal, and pulmonary arteries.
Close examination of the arterial walls revealed an inner
layer of unstained cells corresponding to the endothelium
(Fig. 4D), confirming that enhancer expression is confined
to the SMCs of the vessels. Contrary to the robust expres-
sion of the CRP1-5.0-LacZ transgene within the arteries,
LacZ signal was notably absent from the veins. We failed to
detect LacZ expression in any venous tissues, including the
pulmonary veins and the vena cava (Figs. 4E and 4F).
Likewise, expression was also noticeably absent in the
SMCs of visceral tissues. Beyond embryonic day 13, SMCs
are abundant in the forming visceral organs, such as the
lungs, stomach, and intestine, yet, we never detected ex-
pression of the transgene in these visceral organs. Note the
absence of expression within the abdominal cavity in Fig.
4B, and bronchial tubes in Fig. 4E. This is in contrast to the
endogenous gene, which in addition to arterial smooth
muscle expression is also present in both venous and
visceral SMCs (Henderson et al., 1999). The arterial-
restricted expression of the CRP1-5.0-LacZ transgene per-
sisted in neonates and into adulthood (Fig. 4G, and data not
shown). Interestingly, the coronary arteries of the heart did
not show appreciable LacZ expression (Fig. 4G, and data not
shown). Very weak punctate staining was observed in the
coronary stems of adult hearts, indicating that a small
minority of coronary SMCs expressed the transgene. The
specific activity of the CRP1-5.0 enhancer to arterial SMCs
demonstrates that the CRP1 gene possesses distinct regu-
latory elements for expression within arterial versus venous
and visceral SMCs. Moreover, the absence of expression in
the coronary arteries reveals that the CRP1-5.0 enhancer is
regulated by specific subprograms within select populations
of arterial SMCs.
Cell-Specific Expression of the CRP1–5.0 Enhancer
In the heart, LacZ expression persisted in the outflow
tract during vessel remodeling and was maintained in the
outflow vessels in adult mice (Figs. 4B and 4G). The weak
punctate staining within the ventricles of embryos was
similarly observed postnatally (Fig. 4G). Although this
expression was consistently present, we could not deter-
mine whether it marked a distinguished subset of cells
within the ventricular chambers. In the atria, LacZ expres-
sion was absent throughout development (Figs. 3C and 4F),
© 2001 Elsevier Science. Ahowever, neonate and adult mice exhibited diffuse trans-
gene expression within the atrial chambers (Fig. 4G). Addi-
tional structures that were stained in the heart included the
cells of the aortic valve and the atrio-ventricular cushion
(Fig. 4F). The dynamic expression of the CRP1-5.0-LacZ
transgene in the heart reveals that this enhancer is respon-
sive to precise temporospatial cues that reflect transitional
events and distinct properties of these cardiac cells. Cell-
specific expression of the CRP1-5.0 enhancer was also
evident within mature skeletal muscle. In embryos at
E14.5, expression was observed in the skeletal fibers of the
body wall muscles (Fig. 4C). This activity remained in the
skeletal muscles of adults, but it was only present in a
subset of fibers and was modestly expressed in comparison
to the intense staining of the vasculature (data not shown).
The decline in activity of the CRP1-5.0-LacZ transgene in
the mature skeletal fibers is consistent with the observed
decrease of CRP1 transcript accumulation in adult skeletal
muscle tissue (Henderson et al., 1999).
In addition to the expression of the CRP1-5.0-LacZ trans-
gene in smooth, cardiac, and skeletal muscle, we detected
LacZ signal in a few additional cell types. Beginning at
E12.0, LacZ expression was observed in the perichrondral
mesenchyme of the maxillae and mandibles, and 1 day later
became apparent in the primitive hair follicles of the
whiskers (Figs. 4A and 4C). Expression of the transgene in
these structures was maintained in older embryos and adult
mice. Also, transient LacZ activity was observed in the
inner medulla of the kidney between E13.5 and E14.5 (Fig.
4B). The activity of the CRP1-5.0-LacZ transgene in these
tissues is reflective of CRP1 transcripts and indicates that
additional muscle-independent regulatory elements are
present within the enhancer.
Analysis of the CRP1–5.0 Enhancer in Cultured
Cells
To define more precisely the critical elements of the
CRP1-5.0 enhancer, we analyzed the expression of the
entire enhancer and portions of it in cultured cells. En-
hancer fragments were cloned upstream of the SV40 pro-
moter in the pGL3-Luciferase reporter vector and their
activities were measured by transient transfection followed
by luciferase quantitation. In pulmonary arterial (PAC1)
smooth muscle cells, the CRP1-5.0 enhancer exhibited a
fivefold increase in activity over the parental luciferase
construct (pGL3-Luc), whereas in 10T1/2 fibroblasts, the
enhancer displayed basal activity (Fig. 5A). The activity of
the CRP1-5.0 enhancer was tested in both orientations
relative to the SV40 promoter and produced comparable
results. Two overlapping fragments CRP1-3.7 and CRP1-
3.0, containing 59-most and 39-most sequences, respec-
tively, exhibited similar levels of activity relative to CRP1-
5.0. Similarly, an internal 1.9-kb (CRP1-1.9) fragment
retained an activity level that was equivalent to the entire
CRP1-5.0 enhancer.We additionally examined enhancer activity in C2C12
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(BAEC) (Fig. 5B). Given that the CRP1-5.0-LacZ transgene
was active in skeletal muscle and silent in the endothe-
lium, we anticipated this specificity would be reflected in
culture. Indeed, the CRP1-5.0 enhancer exhibited appre-
ciable activity in C2C12 cells cultured in both growth and
differentiation conditions. Luciferase quantitation of cells
transfected with the entire 5-kb fragment had activity that
was approximately ninefold above basal level. Likewise, the
three overlapping constructs showed comparable activity
relative to the 5-kb fragment. As in PAC1 cells, the 1.9-kb
fragment was sufficient for full enhancer activity within
C2C12 cells, indicating that the essential elements for both
smooth and skeletal muscle expression are confined to a
common region. Conversely, the CRP1 enhancer fragments
exhibited basal activity in aortic endothelial cells. Thus,
the cell-type-specific expression of the CRP1-5.0 enhancer
in culture is consistent with the activity of the enhancer in
transgenic animals, and suggests that the critical elements
reside within the 1.9-kb fragment.
Sequence analysis of CRP1-5.0 enhancer revealed
consensus-binding sites for numerous transcription factors.
Within the 1.9-kb enhancer region, multiple Sp1, AP-2, and
GATA-factor binding motifs were identified (Fig. 6). Of
particular interest, we identified a single CArG element
that differs from the canonical CArG consensus (CC(A/
T)GG) by a single G within the AT-rich core (Treisman,
1992). SRF binding to CArG boxes is centrally important for
muscle-specific transcription, yet, CArG elements have
been shown to possess functional diversity in the control of
gene expression within discrete muscle cell populations
(Mack and Owens, 1999; Manabe and Owens, 2001; Solway
et al., 1998). We therefore were interested in further inves-
tigating the functional properties of the CArG element in
the CRP1-5.0 enhancer.
Binding of SRF to the CRP1–5.0 Enhancer
To determine whether SRF was capable of binding to the
CArG box in the CRP1-5.0 enhancer, we performed gel
mobility shift assays with the CRP1-CArG element as a
probe (Fig. 7A). From nuclear extracts derived from both
10T1/2 and PAC1 cells, we detected prominent complexes
that displayed a similar mobility. The shifted complexes
were abolished by addition of 100-fold molar excess of an
unlabeled SRE (serum response element), the prototypical
SRF binding site from the c-fos gene (Treisman, 1992).
Likewise, the cognate CRP1-CArG element effectively
eliminated the complexes, while a mutated CRP1-CArG
sequence (mutCArG) did not compete for binding. The
mutated CRP1-CArG element differs from the wild-type
sequence by a two-nucleotide change of a C and G flanking
the A/T-rich core. These nucleotides are invariant in con-
sensus CArG elements and are essential for SRF binding
(Shore and Sharrocks, 1995). In an attempt to identify the
protein(s) within these complexes, reactions were incu-
bated with antibodies specific to SRF or YY1, another
© 2001 Elsevier Science. ACArG-binding factor (Gualberto et al., 1992). Addition of
the SRF antibody resulted in a supershift of the CRP1-CArG
probe, demonstrating that SRF was present within the
bound complexes. In contrast, inclusion of the YY1 anti-
body failed to supershift the CArG-bound protein(s).
From our gel mobility shift assays we determined that
SRF forms a complex with the CRP1-CArG element. We
next sought to examine whether overexpression of SRF
could transactivate the CRP1-5.0 enhancer in 10T1/2 cells,
where the enhancer is inactive (Fig. 5A). To evaluate this,
SRF expression constructs were cotransfected with the
CRP1-5.0-Luciferase reporter (CRP1-5.0-Luc) and assayed
for enhancer activity. As shown in Fig. 7B, SRF failed to
transactivate the CRP1-5.0-Luc reporter, inferring that ad-
ditional factors, that are absent from fibroblasts, are re-
quired for enhancer activity. Alternatively, the enhancer
could be maintained in an inactive state in 10T1/2 cells
by repressor proteins, which may potentially block SRF’s
binding. To determine whether SRF was capable of bind-
ing to the CRP1-5.0 enhancer in 10T1/2 cells, a fusion
construct, consisting of full-length SRF linked to the
potent activation domain of the viral protein VP16, was
cotransfected with the CRP1-5.0-Luc. Transfection of
SRF-VP16 resulted in a 14-fold increase in activation of
the CRP1-5.0 enhancer relative to the CMV control,
indicating that SRF is able to bind to the enhancer.
Moreover, the CRP1-5.0 enhancer containing the mu-
tated CArG element (CRP1-5.0mutCArG-Luc) was only
weakly activated by SRF-VP16, verifying the requirement
of the CArG element for SRF’s activity. The CRP1-
5.0mutCArG-Luc was activated 2.8-fold by SRF-VP16,
although the mutated CArG element was incapable of
binding SRF in a mobility shift assay (Fig. 7A, and data
not shown). Whether this modest activity is due to
low-level binding or recruitment of SRF-VP16 to the
enhancer is currently unknown.
CArG Box-Dependent Activity of the CRP1–5.0
Enhancer
Our analysis of the CRP1-CArG element suggests that it
serves to activate the CRP1-5.0 enhancer in muscle cells by
binding SRF. We next wanted to investigate whether the
muscle-specific expression of the CRP1-5.0 enhancer was
dependent on this CArG sequence, and furthermore, if
enhancer expression in smooth, cardiac, and skeletal
muscle cells was equally influenced by this CArG se-
quence. To examine the requirement of the CArG box for
CRP1-5.0 enhancer activity, we generated a LacZ transgene
containing the CRP1-5.0 enhancer with a mutated CArG
element. LacZ activity of the mutant transgene was evalu-
ated in four independent F0 embryos between days E11.5
and E12.0. Embryos containing the mutant enhancer exhib-
ited a dramatic loss of LacZ expression compared to the
wild-type transgene (Figs. 8A and 8B). Expression was
completely abolished in the vasculature, demonstrating
that the CArG element is essential for CRP1-5.0 enhancer
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days of gestation. Within the outflow tract and somites,
LacZ expression was barely detectable, and significantly
less than the robust expression of the wild-type enhancer.
Interestingly, within the perichondral mesenchyme of the
maxillae and mandibles, the expression of the CRP1-
5.0mutCArG-LacZ transgene was the same as the wild-type
enhancer. This result indicates that expression of the en-
hancer in these nonmuscle cell types is CArG box-
independent, and further substantiates the specific require-
ment of the CRP1-CArG element for the control of CRP1
transcription in smooth, cardiac, and skeletal muscle cells.
We additionally tested the CRP1-5.0mutCArG enhancer
in cultured muscle cells. In PAC1 and C2C12 cells, the
CRP1-5.0mutCArG enhancer exhibited activity that was
approximately twofold less than that of wild-type (Fig. 8C).
The relaxed requirement for the CArG element in cultured
cells, compared to that observed in transgenic mice may
reflect slight alterations in regulatory programs attributable
to culturing conditions. Thus, in transgenic mice and in
culture, the CRP1-5.0 enhancer is dependent on the CArG
box for its full activity, verifying the importance of this
element for expression of the CRP1 gene in distinct muscle
cell populations.
DISCUSSION
It is well known that smooth muscle cells (SMCs) are
phenotypically diverse; however, the regulatory pathways
that control gene expression in distinct SMC populations
have not been well established. As a means to elucidate the
molecular mechanisms that govern smooth muscle gene
expression, we isolated and characterized the CRP1 gene. In
this report, we describe the identification of a 5-kb regula-
tory element within the CRP1 gene that is sufficient for
expression in arterial SMCs, the outflow tract and the
somites. We further provide evidence that suggests a role
for SRF in the control of the CRP1-5.0 enhancer by demon-
strating the requirement of the CArG box for muscle-
specific enhancer activity.
Evolutionary Properties of the CRP1 Gene
Characterization of the CRP1 gene revealed a genomic
organization that was virtually identical to the CRP2 gene
within the coding region. However, the 59 regions of these
genes are divergent from one another. CRP1 contains two 59
noncoding exons from which transcription initiation can
occur in SMCs (Fig. 1). In contrast, CRP2 encodes only one
59 exon and has a single promoter (Yet et al., 1998). By
sequence comparison, the CRP2 exon could not be aligned
with either of the CRP1 exons, but its location within the
gene suggests that it is analogous to exon 1B. Interestingly,
the human CRP1 genomic region was reported to have only
one 59 exon (Wang et al., 1992), which by sequence align-
ment resembles exon 1B of the mouse CRP1 gene. It is not
© 2001 Elsevier Science. Aknown whether the human CRP1 gene has retained the 1A
exon. The divergence of the 59 untranslated regions of CRP1
and CRP2 indicates that these genes have evolved to utilize
different regulatory strategies. This is substantiated by the
observed differences in transcript expression patterns.
CRP2 is widely expressed in mesenchymal cells and arterial
SMCs within the developing mouse embryo, whereas CRP1
is more restricted to muscle lineages (Henderson et al.,
1999; Yet et al., 1998). Characterization of the CRP2
regulatory elements revealed an approximate 5-kb region
upstream of the promoter that was sufficient for arterial
smooth muscle expression (Yet et al., 1998). We also
identified an arterial-expressing element, although the
CRP1-5.0 enhancer is found within an intron downstream
of the 1B exon (Fig. 2). Possibly the vascular enhancers of
these two genes represent a conserved regulatory cassette
that has undergone repositioning as the genes have evolved.
A comparison of the two sequences by an alignment search
did not reveal clear stretches of strong homology. Thus, an
analysis of the essential control elements within these
enhancers may help to resolve the extent of their conserved
properties.
Expression of the CRP1–5.0 Enhancer in
Subpopulations of Muscle Cells
From transgenic analysis of the CRP1 gene we identified
a 5-kb enhancer element (CRP1-5.0) within an intron that is
expressed in select populations of smooth, skeletal and
cardiac muscle cells. The enhancer is first activated in the
vasculature between E8.5 and E9.0, paralleling the expres-
sion of CRP1 transcripts, which are present in the dorsal
aorta at the onset of smooth muscle formation (Henderson
et al., 1999). The LacZ activity of the transgene mirrors the
accumulation of newly forming SMCs of the aortic vessel,
first appearing in a punctate pattern that gradually becomes
uniform with the progression of embryogenesis (Figs. 3A
and 3B). Within the vasculature, the CRP1-5.0 enhancer is
exclusively expressed in the vessels of the arterial system.
This is in contrast to the expression of the endogenous
CRP1 gene, which is also transcriptionally active in venous
SMCs. Similarly, the CRP1-5.0-LacZ transgene is not ex-
pressed in visceral SMCs, while CRP1 transcripts are highly
abundant in visceral tissues. The absence of the CRP1-5.0-
LacZ transgene’s expression in the veins and visceral SMCs
indicates that the control elements for these groups of
SMCs lie elsewhere within the gene, and are independently
regulated. This finding is consistent with the theme of
separate regulatory cassettes for distinct populations of
SMCs. Moreover, the arterial-restricted expression further
emphasizes the phenotypic diversity of SMCs and brings
into question the extent of their common lineage. Within
the arterial system, the CRP1-5.0 enhancer is not active in
the coronary arteries. Coronary SMCs originate from the
dorsal mesocardium and have a distinct lineage apart from
the SMCs of aortic media, which could possibly explain the
difference in CRP1-5.0 enhancer activity. Regulatory diver-
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5.0 enhancer is active in a region-specific manner that is
largely confined to the cells of the outflow tract. This
expression, again, differs from CRP1 transcripts, which are
present in the entire heart during embryogenesis. Thus, as
in SMCs, the regulatory elements that drive the expression
of CRP1 in cardiac cells are separate and distinctly regu-
lated.
The expression pattern of the CRP1-5.0 enhancer closely
resembles that of the LacZ transgene derived from a 445-bp
fragment of the SM22a promoter (Li et al., 1996; Moessler
et al., 1996). Both transgenes are temporally activated in
embryos just prior to E9.0, and are restricted to arterial
SMCs, the cardiac outflow tract, and the somites. These
enhancers are only sufficient for a portion of their respec-
tive genes expression, as the transcripts of both CRP1 and
SM22a are present in all SMCs and chambers of the heart.
The superimposable expression of the two transgenes indi-
cates that these genes share a conserved regulatory cassette
and a common transcriptional program, which has been
evolutionarily preserved. Furthermore, the activity of these
enhancers in precise subgroups of smooth, cardiac, and
skeletal muscle cells infers that common myogenic subpro-
grams are utilized among the different muscle cell types.
Requirement of the CArG Element for CRP1–5.0
Enhancer Activity
Individual CArG boxes are uniquely required for the
expression of genes in subpopulations of myogenic cells,
indicating that CArG elements are functionally diverse
(reviewed in Solway et al., 1998; Reecy et al., 1998). In our
analysis, we identified a single CArG consensus sequence
within the 5-kb intronic enhancer (CRP1-5.0) that is ca-
pable of binding SRF in mobility-shift assays, and is neces-
sary for enhancer activation by SRF-VP16 (Fig. 7). Contrary
to many smooth muscle genes, which have multiple CArG
elements within their promoter regions, we did not find
CArG sequences in the proximal promoters of CRP1. Be-
cause CRP1 has two transcription initiation sites (Fig. 1),
the functional elements for smooth muscle activity, such as
the CArG box, may be relegated to enhancers that can be
selectively utilized by one or both promoters. Consistent
with this idea, and as we showed, the CRP1-5.0 enhancer is
sufficient for expression in SMCs independently from its
upstream promoter regions.
By mutational analysis, we demonstrated that the CArG
element is essential for the activity of the CRP1-5.0 en-
hancer in arterial SMCs, the cardiac outflow tract, and
somites in embryos at E11.5 and E12.0 days of gestation
(Fig. 8). Moreover, the CArG box is dispensable for enhancer
expression in nonmuscle cells, as demonstrated by the
wild-type activity of the CRP1-5.0mutCArG-LacZ trans-
gene in the perichondral mesenchyme (Fig. 8). Collectively,
our data show that the CArG element in the CRP1-5.0
enhancer is responsible for its muscle-specific function, and
likely serves to activate transcription by binding SRF.
© 2001 Elsevier Science. AFuture studies to determine how SRF selectively activates
the CRP1-5.0 enhancer are an important next step in
defining the accessory components that establish the tran-
scriptional subprograms within muscle cells.
Regulation of CRP1 and Other SMC Genes
Although the regulatory pathways that control smooth
muscle-specific gene expression are beginning to be unrav-
eled, many questions remain as to how these genes are
distinctly regulated in subpopulations of SMCs. As was
discussed, the temporospatial expression pattern of the
CRP1-5.0-LacZ transgene closely resembles that of the
SM22a-445-LacZ transgene. Both are expressed in arterial
SMCs and are silent in visceral and venous SMCs, implying
that embedded within these enhancers lie functionally
equivalent regulatory elements that are responsible for
their superimposable and restrictive patterns. Indeed, the
CRP1-5.0 and SM22a regulatory cassettes both contain
essential CArG boxes that bind SRF. The regulatory ele-
ments of the SM22a transgene are confined within a 445-bp
proximal promoter region (Grueneberg et al., 1992; Kim et
al., 1997; Li et al., 1996). Within the promoter reside two
CArG boxes, designated as CArG-far and CArG-near. The
CArG-far element is dispensable for transgene activity
while the CArG-near element is essential (Li et al., 1997). In
comparison, the CRP1-5.0 enhancer resides in an intron and
possesses one CArG element that we show is essential for
its activity (Fig. 8). Despite their reliance on the CArG box
for expression, this alone cannot explain their restrictive
activity, as CArG-dependent binding of SRF is known to be
responsible for the expression of genes in all muscle cell
types (Reecy et al., 1998; Solway et al., 1998). Conse-
quently, the CRP1 and SM22a enhancers must utilize
additional transcriptional regulators for their specific ex-
pression within arterial SMCs. These factors could function
to modulate the activity of SRF, as in the case of the SAP
domain protein myocardin, which is expressed in cardiac
and smooth muscle (Wang et al., 2001), or act indepen-
dently of SRF and the CArG element. The discovery of
these two regulatory elements that have virtually identical
expression patterns presents a unique opportunity for com-
parative analysis to identify the critical components re-
sponsible for their cell-specific expression.
Like CRP1, both the SM-MHC gene and the SMa-actin
gene require sequences within an intron for expression in
SMCs (Mack and Owens, 1999; Manabe and Owens, 2001).
Though, unlike the CRP1-5.0 enhancer, which can function
independently from regions upstream of its promoters,
these genes require additional SMC regulatory sequences
within their promoter regions. Moreover, the intronic se-
quences of SM-MHC and SMa-actin support expression in
both vascular and visceral SMCs, contrasting with that of
the arterial-specific activity of the CRP1-5.0 enhancer. Both
SM-MHC and SMa-actin contain CArG elements within
their intronic enhancers, as well as in their proximal
promoter regions. Each of these CArG boxes has been
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in particular subgroups of muscle cells (Mack and Owens,
1999; Manabe and Owens, 2001). Thus, although each of
the smooth muscle genes is dependent on CArG sequences
for their expression, there are clear differences in their
regulatory strategies. Whether these differences serve a
definitive purpose, or represent gene-specific features that
are of little consequence to their expression, poses an
interesting question.
Our characterization of the CRP1 gene has provided
insight into the transcriptional regulation of CRP1 in
SMCs. These results have laid the foundation for the
dissection and elucidation of the combinatorial interac-
tions, which promote the activation of genes in a smooth
muscle-specific manner. Furthermore, the analysis of an
original smooth muscle-expressed enhancer contributes to
our understanding of the complex regulatory programs that
govern expression within distinct SMC populations.
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